<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:department>London Research Institute (LIF)</gtr:department><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F4EA387A-E17F-480F-9E7A-5C78C6BCD9DB"><gtr:id>F4EA387A-E17F-480F-9E7A-5C78C6BCD9DB</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Cherepanov</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000917"><gtr:id>E6BE1CB8-6B56-4728-B553-60F28B4FE60A</gtr:id><gtr:title>Using prototype foamy virus integrase as a model for detailed structural studies of retroviral DNA integration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000917</gtr:grantReference><gtr:abstractText>To achieve productive infection, HIV must insert a DNA copy of its genome into a chromosome of a human cell. This process is orchestrated by integrase, an enzyme carried by the virus. Once integration is complete, the viral genome becomes a permanent resident in the cell. From there it will initiate production of new infectious particles or it might stay dormant and undetected for a long period of time. Integration is partly responsible for the persistence of HIV infection. Yet, the dependence of HIV on integration is also an exploitable weakness. A new class of antiretroviral drugs disrupts enzymatic activity of integrase taking advantage of this weakness to fight HIV. The main impediment to the development of these drugs, also known as integrase inhibitors, is our limited understanding of the structural aspects of HIV integration. In 2010 we determined the long-sought after three-dimensional structure of retroviral integrase bound to viral DNA ends. For these studies we chose to use IN derived from prototype foamy virus (PFV), which is much more soluble and active when removed from its natural environment compared to most of other retroviral INs. On the other hand, all retroviral integrase enzymes are very similar in their structural makeup. Therefore, although PFV is not a human pathogen, its integrase is an ideal model for experimentation as a proxy for HIV integrase. Crucially, it already allowed us to explain how HIV integrase inhibitors work. 
 The current project aims use the unique biochemical properties of PFV integrase to understand the retroviral integration process down to a fine detail. Using X-ray crystallography as our main tool, we will determine three-dimensional structures of PFV integrase at various stages of the integration process. Furthermore, taking advantage of its similarity to HIV integrase, we will use it to understand how HIV can sometimes evade the action of integrase inhibiting drugs. We will also generate more structural information that drug developers will use to improve potency of integrase inhibitors. Our data will be of substantial value for drug discovery and development by both academic and private groups and will serve to reduce the costs and improve availability of the eventual treatments.</gtr:abstractText><gtr:technicalSummary>Integration of viral DNA into a host chromosome is an essential step in HIV replication, orchestrated by integrase (IN). This virally-encoded enzyme is a validated target for development of antivirals, and the first IN inhibitor, Raltegravir, was recently approved for treatment of HIV-1 infection. The major obstacle for the development of this promising class of drugs remains the paucity of available structural information. Recently, we reported the first crystal structure of retroviral IN in complex with viral DNA ends (intasome) and explained how IN inhibitors inactivate it. For these studies we chose to use IN from prototype foamy virus (PFV). Compared to most retroviral INs, this protein is much more soluble and active when removed from its natural environment. On the other hand, it is very similar to HIV IN both functionally and structurally and, therefore, presents an ideal model for experimentation. 

 In this project we will continue taking advantage of this model. Our preliminary data demonstrate that it now became feasible to obtain diffracting crystals of the retroviral intasome at all key stages of the retroviral DNA integration process. Thus, we will determine a high-resolution X-ray structure of the PFV intasome prior 3?-processing reaction. We will also elucidate the interactions of the intasome with target DNA prior to and post strand transfer. Collectively, these efforts will result in description of the entire retroviral DNA integration process in snapshots of its key intermediates. 

 We will also use PFV IN for structural studies of IN inhibitors. In order to understand the basis for HIV-1 resistance to these drugs, we will determine X-ray structures of PFV intasomes mimicking mutations known to reduce HIV-1 susceptibility to Raltegravir and similar first-generation IN inhibitors. We will also determine a range of PFV intasome co-crystal structures with available first- and second-generation IN inhibitors. The resultant data will be invaluable for the refinement of the IN inhibitor pharmacophore to aid in development of antiretroviral drugs.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-02-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>422808</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>686400</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>National Institute of General Medical Sciences (NIGMS)</gtr:department><gtr:description>NIH P50 Center Grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>2P50GM082251-06</gtr:fundingRef><gtr:id>FE63886E-6CE5-4367-8D48-4436724FB7F7</gtr:id><gtr:outcomeId>pQZ92YxkimE</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>288692</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU FP7 HEALTH-2012-INNOVATION-1 collaborative project</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>305137 HIVINNOV</gtr:fundingRef><gtr:id>4B30B191-A747-430C-9F1E-C9857FDCCA96</gtr:id><gtr:outcomeId>YCvMYpGhb3e</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C66DDCEB-A2BF-4898-9114-5CA747948439</gtr:id><gtr:title>Retroviral Integrase Structure and DNA Recombination Mechanism.</gtr:title><gtr:parentPublicationTitle>Microbiology spectrum</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7556856c4f70836893ec054ab43f8aab"><gtr:id>7556856c4f70836893ec054ab43f8aab</gtr:id><gtr:otherNames>Engelman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2165-0497</gtr:issn><gtr:outcomeId>5675e721e5008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22C896D5-81E5-494A-9597-4F07C238E02C</gtr:id><gtr:title>HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88cc0b3857e4454158c5b9ddf455220"><gtr:id>f88cc0b3857e4454158c5b9ddf455220</gtr:id><gtr:otherNames>Wang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_16530_20_23042676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C356E20-4D0F-43E9-AED7-CF9F6B432532</gtr:id><gtr:title>The structural biology of HIV-1: mechanistic and therapeutic insights.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7556856c4f70836893ec054ab43f8aab"><gtr:id>7556856c4f70836893ec054ab43f8aab</gtr:id><gtr:otherNames>Engelman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>pm_16530_20_22421880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>506E294A-9CC8-461A-912E-205E6417D4BF</gtr:id><gtr:title>The mechanism of retroviral integration from X-ray structures of its key intermediates.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67c749d627f6a6bccbe386923cc5a048"><gtr:id>67c749d627f6a6bccbe386923cc5a048</gtr:id><gtr:otherNames>Maertens GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>D1EHBAn1AQo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96A8E6CB-AA9B-416D-8A3E-59D825602F8A</gtr:id><gtr:title>Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2425a4d328ce2edcb596c40787925c07"><gtr:id>2425a4d328ce2edcb596c40787925c07</gtr:id><gtr:otherNames>Hare S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>aRwqBm1ykHY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED8A0373-1246-415F-B19B-14975414C4E3</gtr:id><gtr:title>Structural insights into the retroviral DNA integration apparatus.</gtr:title><gtr:parentPublicationTitle>Current opinion in structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2459210727b755d74eb3437f6b1b30aa"><gtr:id>2459210727b755d74eb3437f6b1b30aa</gtr:id><gtr:otherNames>Cherepanov P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-440X</gtr:issn><gtr:outcomeId>h5XccZj88Rd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9478CFBB-11B6-4C42-B6B9-C265063BA623</gtr:id><gtr:title>Structural biology of retroviral DNA integration.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93f8556619f3487d06c35513ec7d86fb"><gtr:id>93f8556619f3487d06c35513ec7d86fb</gtr:id><gtr:otherNames>Li X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>H8pVUN9hc6Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC3805C7-099F-447B-80A3-7B3FB3248729</gtr:id><gtr:title>3'-processing and strand transfer catalysed by retroviral integrase in crystallo.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2425a4d328ce2edcb596c40787925c07"><gtr:id>2425a4d328ce2edcb596c40787925c07</gtr:id><gtr:otherNames>Hare S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_16530_20_22580823</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04DB7BF2-9647-4F03-9A7E-0F5043991573</gtr:id><gtr:title>Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b120e243d5b3ea1c57d6b1d8bf5ea0ef"><gtr:id>b120e243d5b3ea1c57d6b1d8bf5ea0ef</gtr:id><gtr:otherNames>M?tifiot M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>pm_16530_20_23075516</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000917</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>